Design, synthesis, and preliminary biological evaluation of catalpol propionates as antiaging drugs

Chunhong Dong1*, Shuanglin Liu1, Xiaodong Cheng2, Qiang Wang3, Shiqing Jiang1 and Guoqing Wang2*

Abstract
In this paper, catalpol propionylated analogs (CPs) were designed as drug ligands of glutathione peroxidase (GSH-Px) based on molecular docking (MD) using Surflex-Docking method. The calculated total scores (Total_score) and C log P of CPs are higher than that of catalpol, which show that the CPs maybe served as potential lead compounds as new antiaging drugs. Furthermore, the maximum Total_score of isomers in one group CPs is often not that the molecule with minimum energy structure. These show that the CPs docking with GSH-Px maybe not only affected by the molecular energy, but also affected by their conformations. The CPs were synthesized by esterification of catalpol with propionic anhydride using pyridine as solvent and acid banding agent, DMAP as catalyst, reaction at specific temperature. The synthesized perpropionylated catalpol analog (CP-6) was determined by NMR, FT-IR, HRMS, and HPLC, and the synthesis process was optimized by means of orthogonal experimental design. Subsequently, CP-6 was screened for cells viability by MTT assay, the results show that the CP-6 can effectively reversed STZ-induced reduction of cells viability, and CP-6 has potential antiaging activity.

Keywords: Molecular docking, Synthesis, Catalpol propionate, Antiaging drug

Introduction
Aging is closely associated with diverse chronic diseases, such as hypertension, diabetes, and multiple cancers, etc. [1–3]. With the trend of global aging and the improvement of living standards, health problems caused by aging and aging-associated diseases have become increasingly prominent [2, 3]. It is well accepted that the most significant determinant of aging is oxidative damage caused by overproduction of reactive oxygen species (ROS) [4–6]. Meanwhile, ROS is expected to play an additional role in aging by directly or indirectly damaging the glutathione peroxidase (GSH-Px) and other antioxidant [7]. More and more evidences demonstrate that there is a positive relationship between aging and immune dysfunction [8–10]. The agents with anti-oxidant and/or immunomodulatory functions might be of preventive or potential therapeutic value in aging-associated diseases [11].

The therapeutic efficacy of biologically active natural compounds offers useful platform for developing new antiaging drugs [12, 13]. Catalpol is belong to iridoid glucoside, richly in roots of Rehmannia glutinosa Libosch [14]. It is well known that catalpol has multiple pharmacological activities, including anti-inflammatory and antioxidative effects [14–24]. However, there is no reported that catalpol used as clinical drug in the treatment of age-related diseases because of its blood–brain barrier caused by low lipophilicity and fast metabolism in body [9]. It is necessary to improve its lipophilicity, reduce its blood–brain barrier, increase its utilization in vivo, and modify its structure for used as antiaging drugs.

Molecular docking (MD) is involved in placing the target compound (ligand) into the binding site of a receptor, and finding the appropriate binding position within the...
receptor. Surflex-Dock was applied to perform MD using empirical scoring functions and a patented search engine to dock ligand into a protein's binding site [25, 26]. Surflex-Dock scores (Total_score) were expressed in $-\log_{10}(K_d)$ units to represent binding affinities, and the compounds with higher Total_score can be used as potential antiaging drugs.

In this paper, Surflex-Dock was used to investigate the docking binding affinities of the designed catalpol propionylated analogs (CPs) with GSH-Px. Total_scores of the designed CPs with different molecular energy and conformations were calculated, and the binding modes between CPs and GSH-Px were visualized. The CPs were synthesized by esterification of catalpol with propionic anhydride in pyridine as solvent and acid banding agent, and the synthesized perpropionylated catalpol analog (CP-6) was preliminarily screened for antiaging activity by MTT assay.

Materials and methods
Catalpol was extracted from Rehmannia glutinosa in laboratory, purity is 98%. All the chemicals and organic solvents used in the synthetic process are AR grade. Propionic anhydride, pyridine, sodium bicarbonate and anhydrous sodium sulfate were purchased from Shanghai Alpha Chemical Co., Ltd., China. Methysilicone oil was purchased from Changzhou Longcheng Organosilicon Co., Ltd., China. Chromatographic grade methanol and acetonitrile were purchased from Tianjin Siyou Fine Chemicals Co., Ltd., China. HPLC were performed using Waters-E2695 (Waters Inc., USA). High resolution mass spectra (HRMS) were recorded by Thermo Fisher-Exactive Obitrap Mass Spectrometer (Thermo Fisher Inc., USA). NMR spectra were recorded on Agilent 400 MHz NMR spectrometer (Agilent Inc., USA). FT-IR spectra were measured on Nicolet iS5 (Thermo Fisher Inc., USA). Solvent CDCl$_3$ used in NMR were obtained from Aldrich Chemical Co., Inc. RE-2000B rotary evaporator is purchased from Zhengzhou Kaipeng Experimental Instrument Co., Ltd., China. Ultrapure water was prepared using Milli-Q Century (Millipore Company, USA).

Structure based antiaging drug design
It has been reported that GSH-Px is one of the most important target enzyme for most antiaging drugs. Therefore, GSH-Px was selected to conduct molecular docking with the designed CPs and predict their antiaging activity according to the consistency scoring function. Tripos force field was utilized for energy minimization, and followed by protomol generation [27]. The protomol was created by extracting the original ligand (PDB ID: 2F8A). All crystal water and small molecular ligands in protein crystals were removed. Hydrogen atoms with essential H-bond orientation and charge were added. In Multi-Channel Surface mode, several active pockets were generated and one of the best docking active pockets is selected, and the relevant side chains were repaired, then the binding mode of the CPs and GSH-Px was calculated by adopting an empirical scoring function and a patented searching engine. The threshold is set to 0.50, and the expansion coefficient is set to 1 to form a prototype molecule for docking in high-precision mode. The original ligand in the active pocket as a reference was used to carry out the docking operation between the receptor and the ligand sets. Subsequently, a series of isomers of CPs were docked at the virtual active site via Geom X method by considering every ligand [28]. The binding affinity of the ligands is predicted in terms of Total_score which is expressed as $-\log_{10}K_d$, where $K_d$ is binding constant.

Procedure for synthesis, characterization and purification of CPs
The synthesis route of CPs is shown as Scheme 1 [29, 30], in which $R_1$, $R_2$, $R_3$, $R_4$, $R_5$, $R_6$=CH$_3$CH$_2$CO/–H, and the number of all the possible isomers is 71.

All the reagents and solvents used in the reaction were dried in the conventional way. To a stirred solution of catalpol (100 mg, 0.27 mmol) in pyridine (5 mL) was added propionic anhydride (0.6 mL, 4.7 mmol). The reaction was terminated until the peak of catalpol was disappeared. The HPLC conditions were set as following: PDA detector (210 nm), Agilent-C18 chromatographic column (1250 x 4.6 mm), column temperature 25 °C, mobile phase as acetonitrile:water (V/V) = 70:30.

After the reaction ended, the mixture was poured into ice water and extracted with 60 mL CH$_2$Cl$_2$ three times. The combined organic layers were washed three times with 90 mL of saturated sodium bicarbonate solution, then dried over with MgSO4 and concentrated.

In order to obtain the optimal reaction conditions in the propionylation of catalpol, the molar ratio of reactant (A), reaction temperature (B), reaction time (C), and concentration of pyridine (D) were set as the variable parameter of synthetic reaction. Conversion rate of CP-6 was set as the target index, and four factors in three levels (shown as Table 1) experiments were carried out and visual analyzed according to the orthogonal experiment design L$_9$ (3$^4$).
MTT assay for cells viability
SH-SY5Y human neuroblastoma cells are related to aging, and the viability of SH-SY5Y cells were detected by MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay [31]. Cells were seeded overnight at a density of $10^5$ cells/well 96-well plates in 100 μL medium. The Cells were co-incubated with 20 μM CP-6 with streptozotocin (STZ, 0.8 μM) for 24 h. Then, the medium was removed and added 0.5 mg/μL MTT. After incubation at 37 °C for 4 h, 100 μL of dimethyl sulfoxide (DMSO) was added to SH-SY5Y cells each well, and the mixture was shaken at a low speed for 15 min to fully dissolve the formazan crystals, followed by the measurement of the absorbance at 490 nm using an SpectraMax i3x spectrophotometer (Molecular Devices, USA).

Results and discussion
Molecular docking study
The structure of catalpol was shown as Scheme 2. It can be seen that there are six hydroxyl groups in its molecule structure, and their positions are indicated as 2′, 3′, 4′, 6′, 6, and 10, respectively. In order to improve its blood–brain barrier and fast metabolism, one to six of the hydroxyl groups were designed to be propionylated as CPs. The designed CPs were docked with GSH-Px using Surflex-Docking method, and the calculated Total_score are shown in Table 2. The Total_score
of the isomers of the CPs in different compound groups with the minimum energy (Emin) and maximum value (TSmax) are shown as Fig. 1. The lipophilicity (C log P) of the CPs evaluated by in silico calculation based on their chemical structures were also shown in Table 2.

It can be seen from Table 2 that the Total score are obviously increased with the increase of the number of propionylated hydroxyl groups. The Total_scores of the CPs are all higher than that of catalpol, and the Total_score reaches maximum when the number of propionylated hydroxyl group is six. It also can be seen from Table 2 that the C log P are also increased with the increase of the number of propionylated hydroxyl groups, which indicates that the lipophilicity increased while propionylation of the hydroxyl groups in catalpol. These results indicate that propionylation can improve the antiaging activity of catalpol analogs, and maybe that CP-6 is the best one.

Meanwhile, it can be seen from Fig. 1 that the maximum Total_score in one group isomers is not the CP

| Number | Position | Total_score | C log P | Position | Total_score | C log P |
|--------|----------|-------------|--------|----------|-------------|--------|
| 0      |          | 3.75        | -4.38  |          |             |        |
| 1      | 2'       | 4.04        | -3.36  | 6'       | 5.31        | -3.60  |
|        | 3'       | 6.16        | -3.00  | 10''     | 4.98        | -2.95  |
|        | 4''      | 5.00        | -4.31  | 6        | 4.70        | -2.95  |
| 2      | 4'', 6'' | 5.28        | -2.88  | 4', 10   | 5.67        | -2.88  |
|        | 2', 3'   | 4.83        | -2.88  | 2', 3'   | 5.68        | -2.28  |
|        | 3', 6'   | 5.24        | -2.23  | 3', 6    | 6.14        | -1.57  |
|        | 6', 10    | 5.35        | -2.17  | 3', 10   | 6.11        | -1.57  |
|        | 6', 6    | 5.93        | -2.17  | 2', 10   | 8.25        | -2.22  |
|        | 3', 4'   | 5.72        | -2.93  | 2', 6    | 5.56        | -2.22  |
|        | 2', 4'   | 7.80        | -2.93  | 6, 10    | 5.24        | -1.52  |
| 3      | 4', 6', 10| 6.73        | -1.45  | 2', 4', 6| 6.51        | -1.50  |
|        | 3', 4', 6' | 6.55        | -1.50  | 2', 3', 4' | 6.73     | -1.55  |
|        | 2', 4', 6' | 6.08        | -1.50  | 3', 4', 6| 6.38        | -1.50  |
|        | 4', 6', 6| 7.69        | -1.45  | 3', 4', 10| 6.19       | -1.50  |
|        | 3', 6', 6| 8.33        | -0.80  | 4', 6', 10| 7.15        | -1.45  |
|        | 3', 6', 10| 7.65        | -0.80  | 3', 6', 10| 5.74        | -0.14  |
|        | 2', 3', 6' | 6.41        | -1.50  | 2', 3', 6| 6.24        | -0.85  |
|        | 2', 6', 6 | 6.96        | -1.45  | 2', 3', 10| 6.48        | -0.85  |
|        | 2', 6', 10| 6.67        | -1.45  | 2', 6', 10| 6.58        | -0.80  |
|        | 2', 4', 10| 6.25        | -1.50  | 6', 6', 10| 7.16        | -0.74  |
| 4      | 2', 6', 10| 7.25        | -0.02  | 2', 4', 6, 10| 6.56       | -0.07  |
|        | 2', 3', 4', 6'| 5.31        | -0.12  | 3', 4', 6, 10| 8.06       | -0.07  |
|        | 3', 4', 6, 6| 7.45        | -0.07  | 2', 3', 6, 10| 7.18       | 0.58   |
|        | 3', 4', 6, 10| 9.19        | -0.07  | 2', 4', 6', 6| 6.62       | -0.07  |
|        | 2', 3', 6, 10| 7.15        | -0.07  | 2', 4', 6', 10| 8.15       | -0.07  |
|        | 2', 3', 6, 6| 5.92        | -0.07  | 4', 6', 10| 7.34        | -0.01  |
|        | 2', 3', 4', 6| 5.46        | -0.12  | 3', 6', 10| 6.35        | 0.64   |
|        | 2', 3', 4', 10| 7.36        | -0.12  |          |             |        |
| 5      | 2', 3', 6, 10| 7.90        | 1.36   | 2', 4', 6', 6, 10| 8.02       | 1.36   |
|        | 2', 3', 4', 6', 6| 7.38        | 1.31   | 2', 3', 4', 6, 10| 7.89       | 1.31   |
|        | 2', 3', 4', 6', 10| 9.00        | 1.31   | 3', 4', 6', 10| 7.97       | 1.36   |
| 6      | 2', 3', 4', 6, 10| 9.88        | 2.74   |          |             |        |

1. Number of propionylated hydroxyl groups in CP
2. Positions of propionylated hydroxyl groups in CP
3. The isomer with minimum molecular energy
with the minimum energy of molecule structure. This indicates that the pharmacological activity and chemical stability of CPs maybe different, and suitable synthesis conditions should be selected for producing pharmacological active structure.

The patterns of interaction between CP-5, CP-6, which Total score are higher than seven and C log $P$ are higher than 1.3, and GSH-Px are shown as Figs. 2 and 3, respectively. The rod-like molecules are amino acid residues, and the coarse globular small molecules are CPs. The red represents O, the white represents C, the blue represents N, and the indigo blue represents H. The fluorescent yellow dotted line is a hydrogen bond formed between the small molecules and the amino acid residues surrounding GSH-Px.

In Fig. 2, the oxygen at 4′-position in the carbonyl of CP-5 form two hydrogen bonds with residue LYS112. The 2-position oxygen on six-membered ring of CP-5 forms
a hydrogen bond with hydrogen in the N–H bond of residue ASN77. Two oxygens at 6-position on five-membered ring in CP-5 form two hydrogen bonds with two hydrogens in the N–H bond of residue GLN78, and the oxygen in carbonyl at 6-position of CP-5 forms a hydrogen bond with another hydrogen in N–H bond of residue GLN78. Two oxygens at the 10-position of CP-5 form two hydrogen bonds with two hydrogens in the O–H bond of residue THR149.

In Fig. 3, the oxygen in the carbonyl at 2′-position on the sugar ring of CP-6 forms a hydrogen bond with hydrogen in the O–H bond of residue THR149. Two oxygens at 6′-position in the CP-6 forms two hydrogen bonds with hydrogens in the O–H bond of residue ASN77, respectively. The oxygen at 6′-position in the carbonyl of CP-6 forms a hydrogen bond with residue LYS112. The oxygen on three-membered ring of CP-6 forms a hydrogen bond with hydrogen in the N–H bond of residue GLN82. The oxygen in carbonyl at 10 position of CP-6 form two hydrogen bonds with two hydrogens in the N–H bond of residue ARG179.

Synthesis of CPs and characterization of the synthetic process

Preparation of CPs

The first peracetylated catalpol analogs were synthesized by standard method, shown as Scheme 3 [32]. The designed CPs were tried to be synthesized by substitution of Ac2O with propionic anhydride.

However, no new product was found after the reaction monitored for 36 h. It indicates that the reaction was not carried out in the standard reaction conditions. In order to carry out synthesis process of CPs, DMAP was added as catalyst, and reaction temperature was adjusted to 60 °C. Subsequently, the designed CPs were obtained.

In the synthesis process of CPs, pyridine is not only acts as a solvent, but also acts as an acid binding agent, and DMAP is used as catalyst. The improved standard method is shown as Scheme 1 [29, 30].

Determination of CP-6

The target product was prepared and confirmed by NMR, MS, IR. Its 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) were shown as Fig. 4a, b, respectively. In Fig. 4a, δ 6.30 (1H, dd, J = 1.7, 6.0 Hz, H-3), 5.25 (1H, m, H-3′), 5.16 (1H, t, J = 9.7 Hz, H-4′), 4.95–5.00 (2H, m, H-1′, 2′), 4.93 (1H, dd, J = 4.5, 6.0 Hz, H-4), 4.81–4.86 (2H, m, H-10a, 6), 4.80 (1H, d, J = 5.6 Hz, H-1), 4.10–4.26 (2H, m, H-6′), 4.07 (1H, d, J = 12.8 Hz, H-10b), 3.73 (1H, m, H-5′), 3.65 (1H, s, H-7), 2.61 (1H, dd, J = 7.8, 9.4 Hz, H-9), 2.54 (1H, m, H-5), 2.23–2.44 (12H, m, CH2 × 6), 1.02–1.21 (18H, m, CH3 × 6); In Fig. 4b, δ 174.54, 174.04, 173.71, 173.62, 172.71, 172.52, 141.00, 101.97, 96.60, 94.12, 79.34, 72.38, 70.47, 67.94, 62.71, 61.60, 61.23, 58.62, 41.65, 34.86, 27.44, 27.42, 27.33, 27.32, 27.16, 9.15, 9.07, 8.99, 8.97. Its HRMS (ESI) m/z (pos) was shown as Fig. 5, where C33H46O16 M=698.28, three main m/z peaks [M+H]+ 699.2864, [M+NH4]+ 716.3131, [M+Na]+ 721.2773. Compared the FT-IR spectra of catalpol (shown as Fig. 6, up half) and that of CP-6 (shown as Fig. 6, lower half), it can be seen there are absorptive peaks (cm−1) 3386.4 (OH), 1671.5 (C=O), 1050.6 (CH2OH) and 1131 (CHOH) in catalpol, while the absorptive peak of -OH at 3386.4 cm−1 was disappeared in CP-6, and a strong ester carbonyl absorptive peak was appeared at 1740.8. All above results indicate that the six hydroxyl groups in the catalpol are all esterified.

![Scheme 3](image-url)  
**Scheme 3** Standard synthesized method of peracetylated catalpol analogs

![Fig. 4](image-url)  
**Fig. 4** NMR spectra of CP-6. a 1H NMR spectrum; b 13C NMR spectrum
The residual of the purification process was crystallized from ethanol and obtained 121.27 mg yellow solid. The solid sample was determined by HPLC and shown as Fig. 7 with the purity calculated as 95.03%.

**Characterization of the synthesis process**

The synthetic process of CPs was characterized based on electrospray ionization-high resolution mass spectrometry (ESI-HRMS) method [33]. The mass spectra in negative ion scanning mode of the reaction solution after 1 h was shown as Fig. 8, in which m/z = 463.11878, 519.14278, 575.16583, 631.18878, 687.21187, and 743.23611 are the [M + HCOO]− peaks of CP-1, CP-2, CP-3, CP-4, CP-5, and CP-6, respectively. The semiquantitative relative contents of the CPs can be calculated based on their integral diagram of mass spectra. In this semiquantitative procedure, the yield determination was not based on isolated yields, but it was based on the relative intensiveness of the fragment of CP-6 in the mixtures determined by HRMS.
The visual analysis and variance analysis of the orthogonal test results of propionylation of catalpol were shown in Tables 3 and 4, respectively.

It can be seen from Table 3 that the factors influence order is A > C > B > D, and the optimal reaction conditions for synthesis of CP-6 are A3B2C3D2, i.e., the molar ratio of acid anhydride to catalpol is 12:1, the reaction temperature is 60 °C, the reaction time is 48 h, and the concentration of pyridine is 20 mg/mL, respectively. Meanwhile, it can be seen from Table 4 that the significant influence factor is A and C, and the Error is not significant which shows that the experiment is reliable.

CP-6 was synthesized under the conditions of A3B2C3D2, with the yield 96.71%.

Table 3 Visual analysis of synthesis process

| No. | A  | B  | C  | D  | Yield (%) |
|-----|----|----|----|----|-----------|
| 1   | 1  | 1  | 1  | 1  | 4.47      |
| 2   | 1  | 2  | 2  | 2  | 12.66     |
| 3   | 1  | 3  | 3  | 3  | 11.45     |
| 4   | 2  | 1  | 2  | 3  | 26.31     |
| 5   | 2  | 2  | 3  | 1  | 39.82     |
| 6   | 2  | 3  | 1  | 2  | 30.06     |
| 7   | 3  | 1  | 3  | 2  | 68.82     |
| 8   | 3  | 2  | 1  | 3  | 60.11     |
| 9   | 3  | 3  | 2  | 1  | 64.91     |
| K1  | 9.527 | 33.200 | 31.547 | 36.400 |
| K2  | 32.063 | 37.530 | 34.627 | 37.180 |
| K3  | 64.613 | 35.473 | 40.030 | 32.623 |
| R   | 55.086 | 4.330 | 8.483 | 4.557 |

Table 4 Variance analysis of synthesis

| Factor | Deviation square sum | Freedom | $F^a$ | $F_0^b$ | Significance          |
|--------|----------------------|---------|-------|--------|-----------------------|
| A      | 4601.945             | 2       | 163.497 | 3.63   | Very significant      |
| B      | 28.147               | 2       | 1.000  | 3.63   | –                     |
| C      | 110.649              | 2       | 3.931  | 3.63   | Significant           |
| D      | 35.635               | 2       | 1.266  | 3.63   | –                     |
| Error  | 28.15                | 8       | 1.002  | 3.63   | –                     |

$^a$ Variance $F$

$^b$ Critical value $F_0$

Preliminary biological evaluation of designed CP-6

In the current work, we evaluated the anti-AD effect of CP-6 with activity in preventing against neuronal cell apoptosis by MTT assay. In the assay, STZ was used to
induced cell damage in vitro models, which has been widely used to induce glucose metabolism, neuronal apoptosis and tauopathy through oxidative damage. As demonstrated in Fig. 9, 0.8 mM STZ treatment induced an 29.94% ± 1.48% decrease in cell viability for SH-SY5Y, while co-incubation with 20 μM CP-6 effectively reversed STZ-induced reduction of cells viability. These results indicated that CP-6 has protective effects in neurons, and CP-6 has potential antiaging activity.

Conclusions
The MD results show that the designed CPs maybe are potential antiaging drugs, while the more the number of propionylated hydroxyl groups in catalpol is, the higher of the antiaging activity of the CPs is, and their conformation have effects on their antiaging activity. The designed CPs can be obtained by esterification of catalpol with propionic anhydride in pyridine as solvent and acid banding agent, DMAP as catalyst, and reacted at proper temperature. The optimal reaction conditions for synthesis of CP-6 are molar ratio of acid anhydride to catalpol 12:1, reaction temperature 60 °C, reaction time 48 h, and concentration of pyridine 20 mg/mL, respectively. The MTT assay results indicate that CP-6 has protective effects in neurons and potential antiaging activity.

Acknowledgements
This work was supported by International Cooperation and Exchange Fund China-Thailand Cooperation Project, National Natural Science Foundation of China (No. 8151101082).

Authors’ contributions
CD, GW, and SJ moderated and supervised the project. SL and QW synthesized the designed compounds; XC performed docking study and characterization of the designed and synthesized compounds. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

References
1. Sergeyev PV, Dontsova OA, Berezkin GV (2015) Theories of aging: an ever-evolving field. Acta Naturae 7:9–18
2. Ristow M, Schneisser S (2011) Extending life span by increasing oxidative stress. Free Radic Biol Med 51:327–336
3. Kuliman T, Michalogloou C, Mocci WJ, Peepér DS (2010) The essence of senescence. Genes Dev 24:2463–2479
4. Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J. Gerontol 11:296–300
5. Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24:R453–R462
6. Li SS, Liu M, Zhang C, Tian CY, Wang X, Song XL, Jing HJ, Gao Z, Ren ZZ, Liu WR, Liu WR, Zhang JJ, Jia L (2018) Purification in vitro antioxidiant and in vivo anti-aging activities of soluble polysaccharides by enzyme-assisted extraction from Agaricus bisporus. Int J Biol Macromol 109:457–466
7. Zhao HJ, Li J, Zhang JJ, Wang X, Qiao L, Jia L (2017) Purification in vitro antioxidant and in vivo anti-aging activities of exopolysaccharides by Agrocybe cylindracea. Int J Biol Macromol 102:351–357
8. Deursen JM (2014) The role of senescent cells in ageing. Nature 509:439–446
9. Ginter E, Srimko V, Panakova V (2014) Antioxidants in health and disease. Bratisl Lek Listy 115:603–606
10. Jasiulionis MG (2018) Abnormal epigenetic regulation of immune system during aging. Front Immunol 9:197
11. Kong SZ, Li JC, Li SD, Liao MN, Li CP, Zheng P (2018) Anti-aging effect of chitosan oligosaccharide on policemen. Curr Med Chem 25:3503–3510
12. Xu LW, Kluwe L, Zhang TT, Li SN, Mou YY, Song Z, Ma J, Lu X, Sun JJ (2015) Chinese herb mix tiao-geng-tang possesses antiaging and antioxidative effects and upregulates expression of estrogen receptors alpha and beta in ovariectomized rats. BMC Complement Altern Med 11:137
13. Jiang B, Shen RF, Bi J, Tian XS, Hinchliffe T, Xia Y (2015) Catalpol: a potential therapeutic for neurodegenerative diseases. Curr Med Chem 22:1278–1291
14. Zhang XL, Jiang B, Wang JY, An LL (2008) Comparison of techniques for the extraction of the neuroprotective drug catalpol from Rehmannia glutinosa Libosch. J Biotechnol 136:S471
15. Zhou J, Xu G, Ma S, Li F, Yuan M, Xu H, Huang K (2015) Catalpol ameliorates high-fat diet-induced insulin resistance and adipose tissue inflammation by suppressing the JNK and NF-kappaB pathways. Biochem Biophys Res Commun 467:853–858
16. Tian YY, Jiang B, An LL, Bao YM (2007) Neuroprotective effect of catalpol against MPP (+)-induced oxidative stress in mesencephalic neurons. Eur J Pharmacol 568:142–148
17. Fu K, Piao T, Wang M, Zhang J, Jiang J, Wang X, Liu H (2014) Protective effect of catalpol on lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol 23:405–406
18. Zhang YP, Pan CS, Yan L, Liu YY, Hu BH, Chang X, Li Q, Huang DD, Sun HY, Fu G, Sun K, Fan JY, Han JY (2016) Catalpol restores LPS-elicited rat microcirculation disorder by regulation of a network of signaling involving inhibition of TLR-4 and SRC. Am J Physiol Gastrointest Liver Physiol 311:G1091–G1104
19. Chen Y, Zhang Y, Xu M, Luan J, Piao S, Chi S, Wang H (2017) Catalpol alleviates ovalbumin-induced asthma in mice: reduced eosinophil infiltration in the lung. Int Immunopharmacol 43:140–146
20. Zhang HY, Tang XC (2006) Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27:619–625
21. Jame L (2000) Natural product-derived treatments of neuropsychiatric disorders: review of progress and recommendations. Stud Nat Prod Chem 24:1093–1137
22. Rainer M, Mucke H, Schlaefke S (2013) Ginkgo biloba extract EGb 761A (R) in the treatment of dementia: a pharmacoeconomic analysis of the Austrian setting. Wien Klin Wochen 125:8–15
23. Wang R, Yan H (2006) Progress in studies of huperzine a, a natural cholinesterase inhibitor from Chinese herbal medicine I. Acta Pharmac Sin 27(1):1–26
24. James JF, Bhat KI, More UA, Joshi SD (2018) Design, synthesis, molecular modeling, and ADMET studies of some pyrazoline derivatives as shikimate kinase inhibitors. Med Chem Res 27:546–559
25. Liu ZQ, Yang X, Wang T, Zhu HF (2014) Pharmacokinetics of different administration routes of catalpol. J Southwest Univ (Nat. Sci. Ed.) 36:222–226
26. Ai Y, Wan ST, Sun PH, Song FJ (2011) Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as aurora A kinase inhibitors. Int J Mol Sci 12:1605–1624
27. Jain AN (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46:499–511
28. Sayan DG, Manish KB, Gisela M, Mario DG, Chavali VS, Nargundam MR, Nulgumalli MR (2015) Molecular docking study, synthesis, and biological evaluation of Mannich bases as Hsp90 inhibitors. Int J Mol Sci 80:253–259
29. Dong CH, Wang Q, Wang GQ, Chu ML, Zhu WM (2018-02-27) Propionylation catalpol derivative and preparation method and application thereof: China, CN107739398A [P]
30. Dong CH, Cheng XF, Chu ML, Wang GQ, Zhang HY, Cheng XD, Zhang ZQ, Wang Q, Hu K (2018-11-30) Croton acylated catalpol derivative as well as preparation method and application thereof: China, CN108912183A [P]
31. Rahimi VB, Askari VR, Mousavi SH (2018) Ellagic acid reveals promising anti-aging effects against D-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: a mechanistic study. Biomed Pharmacother 108:1712–1724
32. Pungitore CR, León LG, Garcia C, Martin VS, Tonn CE, Padrónacid JM (2007) Novel antiproliferative analogs of the Taq DNA polymerase inhibitor catalpol. Bioorg Med Chem Lett 17:1332–1335
33. Wang GQ, Chu ML, Li ZX, Yu WH, Dong CH, Wang Q (2018) Application of ESI-HRMS method in analysis of the synthesis process of catalpol propionylated products. J Light Idu 33(3):1–7

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.